Blog

Feb 27, 2024, 8:12 PM
AcuraStem CEO, Sam Alworth, will present on the company's trailblazing approach to amyotrophic lateral sclerosis (ALS) therapies at the MDA Clinical & Scientific Conference on March 4th.
Apr 10, 2023, 3:13 PM
AcuraStem's CEO, Sam Alworth, is set to present on the company’s latest advances in the development of a PIKFYVE antisense oligonucleotide (ASO) therapeutic for diverse forms of FTD (FTD) at the Alzheimer's Drug Discovery Foundation's (ADDF) Defeating Dementia Symposium on April 13.
Mar 20, 2023, 1:54 PM
Fierce Biotech featured AcuraStem's pioneering work with PIKFYVE inhibitors in a recent article highlighting promising developments in treating both genetic and sporadic forms of ALS. The article discusses two recent studies led by Dr. Justin Ichida's lab at USC and the AcuraStem team that have identified drug candidates with potential to transform the disease course for a larger patient population beyond those with known genetic causes of ALS.
Dec 5, 2022, 1:10 PM
Dr. Wen-Hsuan Chang, AcuraStem’s Head of Target Validation to present at the 33nd International Symposium on ALS/MND being held virtually on December 6-9, 2022. Dr. Chang will detail AcuraStem’s development program leveraging its best-in-class  iNeuroRx® platform, composed of patient-derived disease models that accurately recapitulate UNC13A pathology, to develop novel and potent UNC13A antisense oligonucleotide (ASO) drug candidates. UNC13A is one of the most significant genetic risk factors for ALS and FTD.
Dec 6, 2021, 5:01 PM
AcuraStem will present posters at the 32nd International Symposium on ALS/MND.
Sep 18, 2019, 3:09 PM
One of the compounds in a series under development by AcuraStem for ALS, was administered to a neuronal cell line derived from a patient with CMT2A, and showed improved cell survival resulting in the identification as a promising new, preclinical drug candidate for CMT2A
Jan 15, 2019, 11:20 AM
MDA has awarded an MVP grant totaling $300,000 over two years to AcuraStem to support preclinical development of a novel small molecule therapeutic for ALS.
Dec 20, 2018, 10:38 AM
CMT Research Foundation announced today it has entered into a collaborative research partnership with AcuraStem to test thousands of compounds aimed at producing effective treatments for Charcot-Marie-Tooth disease.
Nov 8, 2018, 4:12 PM
Academy Award-winning actress Renee Zellweger encourages the audience to learn more about AcuraStem’s research work in amyotrophic lateral sclerosis (ALS) at the 16th Annual ALS Association Walk to Defeat ALS at Exposition Park in Los Angeles
Apr 20, 2018, 12:58 PM
Dr. Justin K. Ichida was recently profiled by Seema Sharma with Mendeley as a part of their series on stem cells and regenerative medicine. In the interview Dr. Ichida discusses his research, career path, and shares advice for those seeking a transition from postdoctoral to tenure-track.